Last reviewed · How we verify
MGCD265
At a glance
| Generic name | MGCD265 |
|---|---|
| Sponsor | Mirati Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer (PHASE2)
- Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET (PHASE2)
- Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies (PHASE1)
- Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers
- Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies (PHASE1)
- A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer (PHASE1)
- Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MGCD265 CI brief — competitive landscape report
- MGCD265 updates RSS · CI watch RSS
- Mirati Therapeutics Inc. portfolio CI